Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 5
1946 6
1947 14
1948 13
1949 23
1950 32
1951 39
1952 26
1953 24
1954 9
1955 22
1956 15
1957 16
1958 19
1959 41
1960 51
1961 53
1962 46
1963 67
1964 75
1965 45
1966 64
1967 59
1968 89
1969 85
1970 140
1971 148
1972 200
1973 344
1974 392
1975 480
1976 588
1977 600
1978 532
1979 532
1980 494
1981 409
1982 484
1983 533
1984 610
1985 600
1986 667
1987 711
1988 815
1989 1023
1990 1032
1991 1182
1992 1305
1993 1508
1994 1414
1995 1489
1996 1468
1997 1582
1998 1524
1999 1775
2000 1946
2001 2119
2002 2333
2003 2601
2004 2827
2005 3021
2006 3289
2007 3397
2008 3836
2009 3864
2010 4160
2011 4724
2012 5289
2013 5975
2014 6767
2015 7723
2016 9142
2017 10843
2018 12437
2019 14484
2020 19114
2021 23076
2022 24971
2023 25303
2024 26070
2025 238

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233,221 results

Results by year

Filters applied: . Clear all
Page 1
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C. Jiang M, et al. Acta Pharm Sin B. 2021 Oct;11(10):2983-2994. doi: 10.1016/j.apsb.2021.01.003. Epub 2021 Jan 6. Acta Pharm Sin B. 2021. PMID: 34729299 Free PMC article. Review.
Genomic instability remains an enabling feature of cancer and promotes malignant transformation. Alterations of DNA damage response (DDR) pathways allow genomic instability, generate neoantigens, upregulate the expression of programmed death ligand 1 (PD-L1) …
Genomic instability remains an enabling feature of cancer and promotes malignant transformation. Alterations of DNA damage …
Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
Mei Z, Huang J, Qiao B, Lam AK. Mei Z, et al. Int J Oral Sci. 2020 May 28;12(1):16. doi: 10.1038/s41368-020-0084-8. Int J Oral Sci. 2020. PMID: 32461587 Free PMC article. Review.
With the understanding of the complex interaction between the tumour microenvironment and immunotherapy, there is increasing interest in the role of immune regulators in the treatment of head and neck squamous cell carcinoma (HNSCC …
With the understanding of the complex interaction between the tumour microenvironment and immunotherapy, there is increasing interest …
Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
Daste A, Larroquette M, Gibson N, Lasserre M, Domblides C. Daste A, et al. Immunotherapy. 2024 Feb;16(3):187-197. doi: 10.2217/imt-2023-0174. Epub 2023 Dec 21. Immunotherapy. 2024. PMID: 38126161 Review.
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid cancers, including head and neck squamous cell carcinoma (HNSCC). First approved for second-line settings, ICIs are now used for the first-line treatme …
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid cancers, including head and neck …
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B, Young RJ, Rischin D. Solomon B, et al. Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240. doi: 10.1016/j.semcancer.2018.01.008. Epub 2018 Jan 31. Semin Cancer Biol. 2018. PMID: 29355614 Review.
Head and neck squamous cell carcinoma (HNSCC) comprises a heterogeneous group of tumors that arise from the squamous epithelium of the oral cavity, oropharynx, larynx and hypopharynx. ...
Head and neck squamous cell carcinoma (HNSCC) comprises a heterogeneous group of tumors that arise …
An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma.
Wang X, Wu S, Liu F, Ke D, Wang X, Pan D, Xu W, Zhou L, He W. Wang X, et al. Front Immunol. 2021 Nov 19;12:781466. doi: 10.3389/fimmu.2021.781466. eCollection 2021. Front Immunol. 2021. PMID: 34868055 Free PMC article.
Accumulating evidence has demonstrated the ability of ICD to reshape the tumor immune microenvironment through the emission of danger signals or DAMPs, which may contribute to the immunotherapy. Currently, identification of ICD-associated biomarkers that stratify patients …
Accumulating evidence has demonstrated the ability of ICD to reshape the tumor immune microenvironment through the emission of danger signal …
Immunotherapy for Head and Neck Squamous Cell Carcinoma.
Moskovitz J, Moy J, Ferris RL. Moskovitz J, et al. Curr Oncol Rep. 2018 Mar 3;20(2):22. doi: 10.1007/s11912-018-0654-5. Curr Oncol Rep. 2018. PMID: 29502288 Free PMC article. Review.
PURPOSE OF REVIEW: Discussion of current strategies targeting the immune system related to solid tumors with emphasis on head and neck squamous cell carcinoma (HNSCC).This review will outline the current challenges with immunotherapy …
PURPOSE OF REVIEW: Discussion of current strategies targeting the immune system related to solid tumors with emphasis on head and …
Immunotherapy for head and neck squamous cell carcinoma.
Fuereder T. Fuereder T. Memo. 2016;9:66-69. doi: 10.1007/s12254-016-0270-8. Epub 2016 Jun 20. Memo. 2016. PMID: 27429658 Free PMC article. Review.
Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/programmed death ligand 1 (PD-1/PDL-1) and PDL-2, have been recently approved for the treatment of various malignancies and are currently being invest …
Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/programmed …
Immunotherapy for Head and Neck Squamous Cell Carcinoma.
Schoppy DW, Sunwoo JB. Schoppy DW, et al. Hematol Oncol Clin North Am. 2015 Dec;29(6):1033-43. doi: 10.1016/j.hoc.2015.07.009. Epub 2015 Oct 20. Hematol Oncol Clin North Am. 2015. PMID: 26568546 Free article. Review.
Although head and neck squamous cell carcinoma has traditionally been considered to be a very immunosuppressive, or at least nonimmunogenic, tumor type, recent results from clinical studies of immune checkpoint blockade strategies have le …
Although head and neck squamous cell carcinoma has traditionally been considered to be a very immu …
Immunotherapy for head and neck squamous cell carcinoma.
Li Q, Prince ME, Moyer JS. Li Q, et al. Oral Oncol. 2015 Apr;51(4):299-304. doi: 10.1016/j.oraloncology.2014.12.005. Epub 2015 Jan 24. Oral Oncol. 2015. PMID: 25624094 Review.
OBJECTIVES: To review the current state of immunotherapy of head and neck squamous cell carcinoma. MATERIALS AND METHODS: Review of the literature with emphasis on clinical trial data. RESULTS: Patients with head and …
OBJECTIVES: To review the current state of immunotherapy of head and neck squamous cell carcino …
Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
Hanna GJ, Adkins DR, Zolkind P, Uppaluri R. Hanna GJ, et al. Oral Oncol. 2017 Oct;73:65-69. doi: 10.1016/j.oraloncology.2017.08.008. Epub 2017 Aug 17. Oral Oncol. 2017. PMID: 28939078 Review.
The clinical benefit of immunotherapy in recurrent, metastatic head and neck squamous cell carcinoma has fueled interest in revisiting neoadjuvant approaches to complement definitive treatment. ...The potential benefits of neoadjuv …
The clinical benefit of immunotherapy in recurrent, metastatic head and neck squamous cell carc …
233,221 results
You have reached the last available page of results. Please see the User Guide for more information.